Heron Therapeutics | HRTX - Ebitda

Stock Price
1.06
Daily Change
-0.07 -6.19%
Monthly
-12.40%
Yearly
-55.83%
Q1 Forecast
1.15

Heron Therapeutics reported $-3.88M in EBITDA for its fiscal quarter ending in September of 2024.





Ebitda Change Date
ALKERMES USD 100.31M 21.24M Dec/2025
Alnylam Pharmaceuticals USD 145.22M 236.56M Dec/2025
Amarin USD 12.54M 28.57M Jun/2025
ANI Pharmaceuticals USD 65.36M 5.76M Dec/2025
Anika Therapeutics USD -2.69M 4.73M Mar/2025
Arrowhead Research USD 64.2M 223.53M Sep/2025
Eisai JPY 30.1B 6.62B Dec/2025
Esperion Therapeutics USD -27.51M 9.5M Sep/2023
GlaxoSmithKline GBP 3.36B 179M Sep/2025
Heron Therapeutics USD -3.88M 5.63M Sep/2024
Insmed USD -314.19M 31.48M Dec/2025
Ligand Pharmaceuticals USD 150.32M 129.42M Sep/2025
Merck USD 8.39B 1.97B Sep/2025
Nektar Therapeutics USD -31.81M 70K Sep/2023
Neurocrine Biosciences USD 218.4M 28.3M Dec/2025
Omeros USD -47.96M 7.39M Sep/2023
Pacira USD 38.71M 10.65M Dec/2025
Regeneron Pharmaceuticals USD 1.92B 261.9M Sep/2025
Roche Holding CHF 12.68B 2.36B Jun/2024
Surmodics USD 1.53M 485K Sep/2024
Ultragenyx Pharmaceutical USD -156.79M 65.44M Sep/2025
Veracyte USD 42.31M 2.58M Dec/2025
Vertex Pharmaceuticals USD 1.44B 100.4M Sep/2025